NABRIVA THERAPEUTICS PLC Restricted Share Unit Agreement Granted Under 2020 Share Incentive PlanRestricted Share Unit Agreement • March 29th, 2022 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Delaware
This Restricted Share Unit Agreement (this “Agreement”) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the “Company”), and the Participant pursuant to the 2020 Share Incentive Plan (as amended from time to time, the “Plan”).
SIDE AGREEMENT to the Manufacturing Services Agreement effective as of May 08th, 2017Manufacturing Services Agreement • March 29th, 2022 • Nabriva Therapeutics PLC • Pharmaceutical preparations
This Side Agreement (the “Side Agreement”) to the above-mentioned Manufacturing Services Agreement, as assigned by Nabriva Therapeutics GmbH (formerly Nabriva Therapeutics AG) to Nabriva Therapeutics Ireland DAC (the “MSA”), is entered into by and between Patheon UK Ltd, a corporation existing under the laws of United Kingdom, with registered offices at Kingfisher Drive, Covingham, Swindon, SN3 5BZ, UK (“Patheon”) and Nabriva Therapeutics Ireland DAC, an Irish designated activity company, having its registered office at Alexandra House, Office 225/227, The Sweepstakes, Ballsbridge, Dublin 4, D04 C7H2, Ireland (“Customer” or “Nabriva”).
